December 22, 2017 / 9:25 PM / 10 months ago

BRIEF-Biogen Responds To Coverage Recommendation By The Canadian Drug Expert Committee (Cdec) For Spinraza

Dec 22 (Reuters) - Biogen Inc:

* BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA)

* BIOGEN - CDEC’S RECOMMENDATION DISAPPOINTS AS CLINICAL CRITERIA, CONDITIONS LIMIT PATIENTS WITH SMA THAT COULD POTENTIALLY BENEFIT FROM SPINRAZA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below